Akums Group, India’s leading contract development and manufacturing organization (CDMO), has signed a €200 million (approximately ₹1,760 crore) agreement with a global pharmaceutical giant. The collaboration will see Akums manufacture and supply a diverse range of pharmaceutical formulations for the European market, marking a significant milestone in its international growth strategy.
Key Highlights of the Agreement
- Upfront Investment: Akums will receive an initial payment of €100 million (₹880 crore) to facilitate product development and obtain European regulatory approvals for its oral liquid manufacturing facility.
- Production Focus: The deal includes manufacturing multiple SKUs of oral liquid formulations at Akums’ state-of-the-art facilities in India. The products will be marketed across several European nations by the partnering pharmaceutical company.
- Long-Term Supply Commitment: Commercial supplies are set to begin in 2027 and extend through 2032, ensuring a stable supply chain for the partner’s European operations.
Strengthening European Presence
This partnership aligns with Akums’ strategic vision of expanding its footprint in Europe and other regulated markets while supporting India’s “Make in India” initiative. The collaboration not only boosts domestic manufacturing capabilities but also strengthens India’s position as a global hub for pharmaceutical production.
Akums currently operates two European-approved facilities specializing in injectables and oral solids. With this agreement, the company plans to add oral liquid formulations to its portfolio, which already includes tablets, hard gelatin capsules, sachets, ampoules, vials, eye drops, and dry powder injections.
Regulatory Pathway
Akums will initiate the European approval process for its oral liquid manufacturing facility, with approvals for the site and product dossiers expected by the end of 2026. These approvals will pave the way for the seamless entry of Akums’ products into the European market.
Leadership Insights
Sandeep Jain, Managing Director of Akums Group, expressed his enthusiasm for the collaboration:
“This partnership highlights our manufacturing excellence and R&D capabilities. Producing these formulations in India not only reduces costs for our partners but also enhances their supply chain resilience. It sets the stage for further global collaborations.”
Sanjeev Jain, also a Managing Director at Akums, echoed similar sentiments:
“Collaborating with a leading multinational pharmaceutical company is a proud moment for us. This agreement allows us to replicate our domestic CDMO success on a global scale and solidify our presence in Europe’s regulated markets.”
Looking Ahead
This €200 million deal represents a transformative step for Akums Group, reinforcing its commitment to innovation, regulatory excellence, and global market expansion. By combining world-class manufacturing with a robust regulatory strategy, Akums aims to become a preferred partner for pharmaceutical companies seeking high-quality, cost-effective solutions in regulated markets.
